Syndax Pharmaceuticals announced that its drug Revuforj (revumenib), the first FDA-approved menin inhibitor for certain relapsed or refractory acute leukemias, won the 2026 Prix Galien USA award for Best Product for Rare/Orphan Diseases. Revuforj treats adults and children with specific genetic mutations in acute leukemia, offering new targeted therapy options for aggressive cancers with limited treatments. The award highlights the drug's innovative impact on rare leukemia care and Syndax's commitment to advancing cancer therapies. Ongoing trials aim to expand Revuforj's use in combination with other treatments for newly diagnosed patients.
Syndax Pharmaceuticals' Revuforj® (revumenib) won the 2026 Prix Galien USA award for Best Product for Rare/Orphan Diseases. For readers following the health sector, here is Pluang's market snapshot as of Oct 30, 2026 18:43 WIB: out of 150 priced US health stocks, 71 rose and 72 fell. Notable movers include Inovio Pharmaceuticals Inc (INO) with a price of USD 0.86 and a 1-day change of +11.43%, and Stryker Corporation (SYK) priced at USD 277.03 with a 1-day change of -11.03%.
FirstCash Holdings reported a 28% year-over-year decline in operating income for its American First Finance segment and a 15% drop in lease and loan originations for Q3 2026. This led to a 14.75% stock price decline on October 22, 2026. The Law Offic...
Oxford Square Capital Corp. announced its financial results for Q3 2026, reporting a net asset value (NAV) per share of $1.21, down from $1.29 in Q2. The company declared monthly dividends of $0.015 per share for January, February, and March 2027. Ne...
MADD Canada warns Canadians to avoid impaired driving during Halloween, emphasizing the risks of alcohol, cannabis, and drug-related crashes that cause deaths and injuries annually. The organization urges people to plan safe rides, watch for children...
As Halloween approaches, MADD Canada warns against impaired driving caused by alcohol, cannabis, or drugs, which leads to hundreds of deaths and thousands of injuries annually in Canada. The organization urges people to plan safe transportation if co...
Investec Bank Plc, acting as joint broker for SThree Plc, disclosed share transactions on October 29, 2026. The bank purchased and sold 49,799 ordinary shares of SThree Plc at prices ranging between 297.5 and 306.5 per share. No derivative or option ...
